These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 17558308

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
    Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, Schonau A, Gunnarsdóttir K, Olsen KE, Mouridsen H, Ejlertsen B, Danish Breast Cancer Cooperative Group.
    J Clin Oncol; 2005 Oct 20; 23(30):7483-90. PubMed ID: 16234514
    [Abstract] [Full Text] [Related]

  • 4. Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer.
    Pierceall WE, Sprott KM, Heikkinen T, Heikkila P, Alaparthi L, Aittomaki K, Al-Adhami M, Villegas-Bergazzi V, Meyer JL, Kutok JL, Bartkova J, Bartek J, Nevanlinna H, Weaver DT, Blomqvist C.
    Hum Pathol; 2012 Sep 20; 43(9):1363-75. PubMed ID: 22204715
    [Abstract] [Full Text] [Related]

  • 5. Single nucleotide polymorphisms in DNA repair genes XRCC1 and APEX1 in progression and survival of primary cutaneous melanoma patients.
    Figl A, Scherer D, Nagore E, Bermejo JL, Dickes E, Thirumaran RK, Gast A, Hemminki K, Kumar R, Schadendorf D.
    Mutat Res; 2009 Feb 10; 661(1-2):78-84. PubMed ID: 19073198
    [Abstract] [Full Text] [Related]

  • 6. The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D.
    Nielsen KV, Ejlertsen B, Møller S, Jørgensen JT, Knoop A, Knudsen H, Mouridsen HT.
    Acta Oncol; 2008 Feb 10; 47(4):725-34. PubMed ID: 18465341
    [Abstract] [Full Text] [Related]

  • 7. Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer.
    Schrohl AS, Meijer-van Gelder ME, Holten-Andersen MN, Christensen IJ, Look MP, Mouridsen HT, Brünner N, Foekens JA.
    Clin Cancer Res; 2006 Dec 01; 12(23):7054-8. PubMed ID: 17114213
    [Abstract] [Full Text] [Related]

  • 8. Influence of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms on the disease-free survival of breast cancer patients receiving adjuvant 5-fluorouracil/methotrexate-based therapy.
    Paré L, Altés A, Ramón y Cajal T, Del Rio E, Alonso C, Sedano L, Barnadas A, Baiget M.
    Anticancer Drugs; 2007 Aug 01; 18(7):821-5. PubMed ID: 17581305
    [Abstract] [Full Text] [Related]

  • 9. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
    Huang ZH, Hua D, Du X.
    Cancer Chemother Pharmacol; 2009 Oct 01; 64(5):1001-7. PubMed ID: 19247656
    [Abstract] [Full Text] [Related]

  • 10. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.
    Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifert M, Denison U, Mlineritsch B, Steger G, Kwasny W, Stöger H, Bartsch R, Stierer M, Taucher S, Fridrik M, Schippinger W, Greil R, Pötter R, Gnant M, Austrian Breast and Colorectal Cancer Study Group.
    Clin Cancer Res; 2008 Apr 01; 14(7):2082-7. PubMed ID: 18381948
    [Abstract] [Full Text] [Related]

  • 11. Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.
    Tinari N, Lattanzio R, Natoli C, Cianchetti E, Angelucci D, Ricevuto E, Ficorella C, Marchetti P, Alberti S, Piantelli M, Iacobelli S.
    Clin Cancer Res; 2006 Mar 01; 12(5):1501-6. PubMed ID: 16533774
    [Abstract] [Full Text] [Related]

  • 12. DNA repair gene XRCC1 polymorphisms and haplotypes in diffuse large B-cell lymphoma in a Korean population.
    Kim IS, Kim DC, Kim HG, Eom HS, Kong SY, Shin HJ, Hwang SH, Lee EY, Kim S, Lee GW.
    Cancer Genet Cytogenet; 2010 Jan 01; 196(1):31-7. PubMed ID: 19963133
    [Abstract] [Full Text] [Related]

  • 13. Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer.
    Bewick MA, Conlon MS, Lafrenie RM.
    J Clin Oncol; 2006 Dec 20; 24(36):5645-51. PubMed ID: 17116943
    [Abstract] [Full Text] [Related]

  • 14. Alkaline comet assay study with breast cancer patients: evaluation of baseline and chemotherapy-induced DNA damage in non-target cells.
    Kopjar N, Milas I, Garaj-Vrhovac V, Gamulin M.
    Clin Exp Med; 2006 Dec 20; 6(4):177-90. PubMed ID: 17191110
    [Abstract] [Full Text] [Related]

  • 15. Association of the Arg194Trp and the Arg399Gln polymorphisms of the XRCC1 gene with risk occurrence and the response to adjuvant therapy among Polish women with breast cancer.
    Przybylowska-Sygut K, Stanczyk M, Kusinska R, Kordek R, Majsterek I.
    Clin Breast Cancer; 2013 Feb 20; 13(1):61-8. PubMed ID: 23103366
    [Abstract] [Full Text] [Related]

  • 16. Prediction of response to repeat utilization of anthracycline in recurrent breast cancer patients previously administered anthracycline-containing chemotherapeutic regimens as neoadjuvant or adjuvant chemotherapy.
    Yonemori K, Katsumata N, Kaneko M, Uno H, Matsumoto K, Kouno T, Shimizu C, Ando M, Takeuchi M, Fujiwara Y.
    Breast Cancer Res Treat; 2007 Jul 20; 103(3):313-8. PubMed ID: 17063267
    [Abstract] [Full Text] [Related]

  • 17. Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy.
    Hurria A, Brogan K, Panageas KS, Pearce C, Norton L, Jakubowski A, Zauderer M, Howard J, Hudis C.
    Breast Cancer Res Treat; 2005 Jul 20; 92(2):151-6. PubMed ID: 15986124
    [Abstract] [Full Text] [Related]

  • 18. Polymorphisms in three base excision repair genes and breast cancer risk in Thai women.
    Sangrajrang S, Schmezer P, Burkholder I, Waas P, Boffetta P, Brennan P, Bartsch H, Wiangnon S, Popanda O.
    Breast Cancer Res Treat; 2008 Sep 20; 111(2):279-88. PubMed ID: 17922186
    [Abstract] [Full Text] [Related]

  • 19. HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients.
    Ejlertsen B, Jensen MB, Nielsen KV, Balslev E, Rasmussen BB, Willemoe GL, Hertel PB, Knoop AS, Mouridsen HT, Brünner N.
    J Clin Oncol; 2010 Feb 20; 28(6):984-90. PubMed ID: 20038724
    [Abstract] [Full Text] [Related]

  • 20. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
    Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, Bruzzi P.
    J Natl Cancer Inst; 2008 Jan 02; 100(1):14-20. PubMed ID: 18159072
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.